



COVID-19 Health Data Research

12 May 2020 - Weekly update for SAGE & UKRI/DHSC

Authors:

Andrew Morris, Health Data Research UK
Ben Gordon, Health Data Research UK
Carole Morris, Public Health Scotland
Caroline Cake, Health Data Research UK (lead)
Cathie Sudlow, BHF Data Science Centre
Charlie Davie, DATA-CAN
Clara Fennessy, Health Data Research UK
David Seymour, UK Health Data Research Alliance

John Aston, Home Office (SAGE sponsor)
John Deanfield, NICOR
Mark Parsons, Scotland National Safe Haven
Nilesh Samani, British Heart Foundation
Rhoswyn Walker, Health Data Research UK
Ronan Lyons, SAIL Databank (UKRI/DHSC sponsor)
Sara Hiom, CRUK
Tom Denwood, NHS Digital



Insights now generating at pace, some contradictory and require further collaborative analysis or more diverse data – particularly primary care

Priority research questions, studies & insights – 12 May 2020

Priority research questions (short-form)	Studies already working on this:	Insights	Next steps / Outstanding Questions
1. Why do BAME groups have an increased risk of severe COVID-19 outcomes (RQ34, 37)?	<ul style="list-style-type: none"> University Hospitals Birmingham, Pioneer Health Data Research Hub & DECOVID NHSD & PHE CO-CIN ONS & Discover-NOW Health Data Research Hub Imperial College 	Cumulative, but contradictory insights emerging (see details of insights from individual studies here). No clear understanding of observed patterns at present.	<p>Further meta-analysis required to understand variances in observations (ranging from none, to South Asian to Black ancestry impacts) – is this related to confounding e.g. comorbidities or social determinants?</p> <p>Further consortia building ongoing. Likely to require national & more detailed regional/NHS data resources.</p>
2. What impact has COVID-19 having on care home patients? (RQ63)	<ul style="list-style-type: none"> HDR UK North – University of Sheffield & Lancaster Birmingham NHS Trust UCL Bristol 	Ongoing research	<p>Existing research includes: patterns of incidence, infection dynamics, effectiveness of care home testing strategy, impact of hospital discharge patterns.</p> <p>To avoid selection bias – will require national (e.g. HES) and primary care data.</p>
3. How do we best understand and protect vulnerable populations? (RQ 32, 36, 62)	<ul style="list-style-type: none"> HDR UK London (UCL) & Uni of Cambridge and Oxford/Alan Turing Institute 	<p>Underlying health conditions can increase 1 year risk of during the COVID-19 death fivefold.</p> <p>Online, public, prototype risk calculator available here: OurRisk.CoV : http://covid19-phenomics.org/PrototypeOurRiskCoV.html</p>	<p>Lancet publication: 13 May 2020</p> <p>Project in initiation: Understanding vulnerable children using linked NHS Digital (HES), social care and Dept of Education data on ~18million children.</p>
4. What is the impact on treatment and outcomes for non-COVID-19 disease (e.g. cardiovascular) (RQ29)	<ul style="list-style-type: none"> BHF Data Science Centre and UK-wide CVD COVID UK consortium 	Progress towards establishing a Trusted Research Environment for national English data, similar to those in Wales and Scotland, along with rapid reporting of aggregate data from digitally mature hospitals.	Access to data at UK-wide scale enabling impact on a wide range of cardiovascular disorders (acute coronary syndromes, heart failure, stroke, peripheral vascular disease) to be investigated.
5. Do ACE-inhibitors and ARBs increase the risk of severe COVID-19? (RQ57)	<ul style="list-style-type: none"> King's College London UCL Bristol BHF Data Science Centre 	Further evidence confirmed in 1200 acute inpatients in London suggests that there was no evidence for increased severity of disease in patients treated with ACEi or ARB.	Significant risk of selection and “collider” bias (see here) makes further analysis essential – primary care data is vital (for any medication prescribed in primary care). Ongoing national collaborative discussions are being led by the BHF data science centre.

8 COVID-19 weekly taskforce calls with **65** clinical and health data research leaders engaged



1290 academic, industry and NHS participants in COVID-19 Slack channel with 10 sub-channels



62 volunteers in HDR UK's COVID-19 Public & Patient Group



74 health data research questions identified – 28 prioritised



57 COVID-19 pre-print publications



Click [here](#) for a link to the full prioritised list of questions, status, and prioritisation process

Priorities to scale-up data use: 1) access to primary care data 2) moving projects from development to IG scrutiny

COVID-19 dataset availability and status of projects using the data – 12 May 2020

1. Good progress collecting and linking large scale datasets across the national capability but progress on primary care data flows remains slow despite its importance to many priority research questions

Core COVID-19 Datasets available for linkage	England (NHS Digital Data Processing Service)	Scotland (National Data Safe Haven)	Wales (SAIL Databank)	Northern Ireland (Honest Broker Service)
Primary Care	Dark Blue	Dark Blue	Green	To be included for future weeks
UKGov Testing data	Light Blue	Light Blue	Light Blue	
Community Prescribing	Light Blue	Green	Green	
Critical Care	Light Blue	Green	Light Blue	
Personal Demographic Service	Green	Green	Green	
COVID-19 Surveillance Testing	Green	Green	Green	
Secondary Care	Green	Green	Green	
Death registry	Green	Green	Green	

KEY

- Data flows specified but not yet agreed
- Data flows agreed but not yet available for linkage
- Fully available

2. Activity within the national TREs is predominantly at an early stage of development

# of COVID-19 Projects by TRE stage	England (NHS Digital Data Processing Service)	Scotland (National Data Safe Haven)	Wales (SAIL Databank)	Northern Ireland (Honest Broker Service)
In development	30	24	31	To be included for future weeks
Submitted for IG approval	2	2	0	
Approved but not yet active	2	4	3	
Active research taking place	2	3	14	

KEY UK WIDE PROJECTS:

[RECOVERY](#)

[CO-CIN \(ISARIC 4C\)](#)

[COG-UK](#)

CARDIOVASCULAR CONSORTIUM

3. Existing and new environments with > 10 million primary care population coverage are also being set up and utilised for COVID-19 research

- Clinical Practice Research Datalink (CPRD) has been running for more than 30 years. It covers 14 million currently registered patients and has 9 approved COVID-19 studies <https://www.cprd.com/protocol-list>
- OpenSAFELY is a new collaboration between GP System provider TPP with University of Oxford and London School of Hygiene & Tropical Medicine <https://opensafely.org/>. It covers 24 million patients and has work underway across 5 research areas.

NOTES

TRE - Trusted Research Environment

IG - Information Governance